Vitrolife stock
VITR.STSTOVitrolife AB (publ), HealthcareISIN SE0011205202
51Score 51 out of 100, Neutral
Price and trend
77 / 100
Price history
−19% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 22% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 78).
The price is 22% below its 52-week high. Largest decline in 20 years: 85% (November 2021 to July 2026).
Chart figures for advanced users
- SMA 50$10.12
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.71
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)78
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$8.58
- The lowest closing price of the last twelve months.
- Resistance$15.20
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Vitrolife AB (publ) belongs to the Medical (Devices) industry (Sweden) and, with a market value of $1.57B, is number 47 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $346.37M (down 4.7% year on year) and a loss of $504.75M.
- For fiscal 2026, analysts expect on average revenue of $352.8M (up 1.9%) and adjusted earnings per share of $0.44 (up 177.7%).
Show more
- MEQIRI Score 51 out of 100 (Neutral): rank 376 of 714 in Healthcare, median 53.
- Our model puts fair value at $9.11, with the price 31% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 22.5% a year since 2020, Medical (Devices) median 13.8%.Growth 58
Weaknesses
- Margin fallingOperating margin −140.6%, average of the prior years 21.7% (to 2024).Profitability 25
- DilutionShare count up 25% since 2020.Capital allocation 25
- Loss-makingLoss of $499.21M over the last 12 months.Fundamentals 58
Its standout strength is technical analysis, while profitability and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 50 to 51.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $6.50 and expensive above $15.18 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $7.57, at 6.2% it would be $11.41.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 1.9% on the twelve months before. Revenue has grown strongly since 2006, at around 17% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 58%, operating −141%, net −146%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 28 Jan 2027in 77 days
- Last reported
- 22 Oct 2026EPS reported $0.09 (expected $0.10)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.44+1.5%
- Revenue
- $352.8M+1.0%
- Earnings per share
- $0.53+0.5%
- Revenue
- $383.89M+1.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Vitrolife
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 51
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Inspire Medical SystemsINSP $1.8B52
- Embla Medical hf.EMBLA.CO $1.78B67
- EnovisENOV $1.65B45
- Medartis HoldingMED.SW $1.64B54
- Lumexa Imaging HoldingsLMRI $1.53B47
- CONMEDCNMD $1.51B69
- EL.En.ELN.MI $1.48B75
- NovocureNVCR $1.4B30
ETFs that hold Vitrolife
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| WisdomTree Europe SmallCap Dividend UCITS ETFWTES | 0.11% | 0.38% | €86.74M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.05% | 0.30% | €3.43B |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.04% | 0.23% | €319.31M |
Show 5 more
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.02% | 0.30% | €810.11M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.00% | 0.35% | €434.1M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = SEK 9.9317)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.